(Q41666553)

6 October 2017

title

Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism (English)

1 reference

6 October 2017

1 reference

5

Julio S G Montaner

1 reference

6 October 2017

4

Mel Krajden

1 reference

6 October 2017

1

Rosemary M McCloskey

1 reference

6 October 2017

3

Jeffrey B Joy

1 reference

6 October 2017

Richard H Liang

2

1 reference

6 October 2017

P Richard Harrigan

series ordinal

6

1 reference

6 October 2017

Art F Y Poon

series ordinal

7

1 reference

6 October 2017

language of work or name

English

0 references

publication date

10 November 2014

1 reference

Journal of Infectious Diseases

6 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

6 October 2017

volume

211

1 reference

6 October 2017

issue

8

1 reference

6 October 2017

page(s)

1288-1295

1 reference

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Recent developments in the MAFFT multiple sequence alignment program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Biopython: freely available Python tools for computational molecular biology and bioinformatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

The Los Alamos hepatitis C sequence database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

FastTree 2--approximately maximum-likelihood trees for large alignments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Needle exchange is not enough: lessons from the Vancouver injecting drug use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

BEAST: Bayesian evolutionary analysis by sampling trees

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

APE: Analyses of Phylogenetics and Evolution in R language

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Inference of viral evolutionary rates from molecular sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Site-to-site variation of synonymous substitution rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Spidermonkey: rapid detection of co-evolving sites using Bayesian graphical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Inference from Iterative Simulation Using Multiple Sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Evidence for separation of HCV subtype 1a into two distinct clades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

The epidemic behavior of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Genetic history of hepatitis C virus in East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

Statistical Methods in Molecular Evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU613

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU613

1 reference

6 October 2017

1 reference